Associated Papers
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2026
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biorxiv : the Preprint Server for Biology, 2025
Cancer-Related Mutations in the Sam Domains of EphA2 Receptor and Ship2 Lipid Phosphatase: A Computational Study.
Vincenzi M et al.
Molecules (basel, Switzerland), 2024
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S et al.
Peerj, 2022
35070505 (PubMed )
Supplement: peerj-10-12750-s003.xlsx › Supplemental_Table1
Select a paper to view details